SAB Biotherapeutics Inc. (SABSW) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    SAB Biotherapeutics Inc.

    NASDAQ: SABSW · Real-Time Price · USD
    0.02
    -0.02 (-48.98%)
    At close: Jun 09, 2025, 11:03 AM

    SAB Biotherapeutics Income Statement

    Financials in USD. Fiscal year is undefined.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 1.32M 2.24M 23.9M 60.88M
    Cost of Revenue
    		 n/a 3.75M 3.29M 1.65M
    Gross Profit
    		 -3.47M -1.51M 20.61M 59.22M
    Operating Income
    		 -42.91M -38.08M -28.92M -13.39M
    Interest Income
    		 1.29M 584.97K 71.07K 23.11K
    Pretax Income
    		 -34.11M -42.19M -18.72M -17.14M
    Net Income
    		 -34.11M -42.19M -18.74M -17.44M
    Selling & General & Admin
    		 13.98M 20.05M 16.38M 17.09M
    Research & Development
    		 30.25M 16.52M 36.44M 57.18M
    Other Expenses
    		 n/a n/a -23.9M -60.88M
    Operating Expenses
    		 42.91M 36.57M 28.92M 13.39M
    Interest Expense
    		 318.4K 315.28K 301.58K 294.46K
    Selling & Marketing Expenses
    		 n/a -3.75M n/a n/a
    Cost & Expenses
    		 44.23M 40.31M 28.92M 13.39M
    Income Tax Expense
    		 n/a n/a 25.63K 299.95K
    Shares Outstanding (Basic)
    		 9.26M 5.52M 4.35M 2.73M
    Shares Outstanding (Diluted)
    		 9.26M 5.52M 4.35M 2.73M
    EPS (Basic)
    		 -3.68 -7.64 -4.31 -6.38
    EPS (Diluted)
    		 -3.68 -7.64 -4.31 -6.38
    EBITDA
    		 -28.99M -38.13M -15.12M -15.2M
    EBIT
    		 -33.79M -41.88M -18.41M -16.85M
    Depreciation & Amortization
    		 4.79M 3.75M 3.29M 1.65M

    Add to Watchlist